Literature DB >> 1623924

Specificity, T cell receptor diversity and activation requirements of CD4+ and CD8+ clones derived from human melanoma-infiltrating lymphocytes.

M C Pandolfino1, C Viret, N Gervois, Y Guilloux, F Davodeau, E Diez, F Jotereau.   

Abstract

To try to understand the functional significance of human melanoma-infiltrating lymphocytes (TIL), a clonal analysis of the specificity, T cell receptor (TcR) diversity and activation requirements of these lymphocytes isolated from four different tumors was carried out. Supporting the presence of in vivo primed tumor-specific T lymphocytes in these four tumors, a high frequency of the Cd8+ and CD4+ clones, obtained from the TIL cultured for a few days with recombinant interleukin (rIL)-2 and autologous tumor cells, exhibited a restricted lysis or proliferation in response to the autologous tumor cell line. In contrast, no tumor-specific clone was obtained from freshly extracted TIL, suggesting that the frequency of tumor-specific effectors remained low in these tumors. Only the CD8+ clones lysed the autologous tumor cells and their activity was major histocompatibility complex MHC class I restricted. Significant expansion of CD4+ and CD8+ tumor-specific clones required regular restimulation by autologous melanoma cells but also the addition of exogenous IL-2 and of Epstein-Barr virus-transformed B feeder cells. Five different tumor-specific clones, three CD8+ and two CD4+ clones were identified in a single tumor on the basis of their TcR gene configuration. Together, these data suggest that a spontaneous and diverse immune response, mediated by tumor-specific CD4+ as well as CD8+ T lymphocytes, arises in most MHC-bearing human melanomas but that antigen-MHC complex presentation by tumor cells does not, at least in vitro, allow a significant proliferation of these lymphocytes.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1623924     DOI: 10.1002/eji.1830220719

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  6 in total

1.  Human monocyte-derived macrophages and dendritic cells are comparably effective in vitro in presenting HLA class I-restricted exogenous peptides.

Authors:  L Toujas; J G Delcros; E Diez; N Gervois; G Semana; G Corradin; F Jotereau
Journal:  Immunology       Date:  1997-08       Impact factor: 7.397

2.  Human colorectal tumour infiltrating lymphocytes express activation markers and the CD45RO molecule, showing a primed population of lymphocytes in the tumour area.

Authors:  B Ostenstad; T Lea; E Schlichting; M Harboe
Journal:  Gut       Date:  1994-03       Impact factor: 23.059

3.  Culture of tumour-infiltrating lymphocytes from melanoma and colon carcinoma: removal of tumour cells does not affect tumour-specificity.

Authors:  W M Mulder; M J Stukart; M Roos; R A van Lier; J Wagstaff; R J Scheper; E Bloemena
Journal:  Cancer Immunol Immunother       Date:  1995-11       Impact factor: 6.968

4.  A processed pseudogene codes for a new antigen recognized by a CD8(+) T cell clone on melanoma.

Authors:  A Moreau-Aubry; S Le Guiner; N Labarrière; M C Gesnel; F Jotereau; R Breathnach
Journal:  J Exp Med       Date:  2000-05-01       Impact factor: 14.307

5.  A peptide recognized by human cytolytic T lymphocytes on HLA-A2 melanomas is encoded by an intron sequence of the N-acetylglucosaminyltransferase V gene.

Authors:  Y Guilloux; S Lucas; V G Brichard; A Van Pel; C Viret; E De Plaen; F Brasseur; B Lethé; F Jotereau; T Boon
Journal:  J Exp Med       Date:  1996-03-01       Impact factor: 14.307

6.  Suboptimal activation of melanoma infiltrating lymphocytes (TIL) due to low avidity of TCR/MHC-tumor peptide interactions.

Authors:  N Gervois; Y Guilloux; E Diez; F Jotereau
Journal:  J Exp Med       Date:  1996-05-01       Impact factor: 14.307

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.